Vaxcyte
PCVX | NASDAQ
$61.61
-$1.76 (-2.78%)
At close: Nov 16, 2026, 4:00 PM ET
$61.61
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Vaxcyte Company Profile
Company profile explainedCompany Profile
Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia. Beyond its flagship candidate, Vaxcyte is also advancing several other vaccine programs: VAX-XP, designed to offer protection against emergent bacterial strains and counter antimicrobial resistance; VAX-A1, a conjugate vaccine formulation aimed at Group A Streptococcus; and VAX-PG, a novel protein vaccine specifically developed to target the key pathogen responsible for periodontitis. The organization, which was initially established as SutroVax, Inc., officially rebranded as Vaxcyte, Inc. in May 2020. Founded in 2013, its corporate headquarters are situated in San Carlos, California.
Key Executives
| Name | Position |
|---|---|
| Grant E. Pickering | Co-Founder, Chief Executive Officer & Director |
| Andrew L. Guggenhime | President & Chief Financial Officer |
| David McAvoy | Chief Legal Officer, Chief Compliance Officer & Corporate Secretary |
| Whitney Jones | Chief People Officer |
| Elvia Cowan | Senior VP of Finance & Chief Accounting Officer |
| Harp Dhaliwal | Chief Technical Operations Officer |
| James Wassil | Executive VP, Chief Scientific Officer & COO |
| Janet Graesser | Senior Vice President of Corporate Affairs |
| Jeff Fairman | Co-Founder & Vice President of Research |
| Jeff Macdonald | Executive Director of Investor Relations |
| Mikhail Eydelman | Senior VP & General Counsel |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 09, 2026 | 8-K | Current Report |
| Oct 08, 2026 | 424B5 | Filing |
| Oct 08, 2026 | 424B5 | Filing |
| Oct 07, 2026 | 4 | Filing |
| Oct 07, 2026 | 4 | Filing |
| Oct 07, 2026 | FWP | Filing |
| Oct 06, 2026 | 305B2 | Filing |
| Oct 06, 2026 | 424B5 | Filing |
| Oct 06, 2026 | 424B5 | Filing |
| Oct 05, 2026 | 8-K | Current Report |
Vaxcyte
| Country | United States |
| IPO Date | Jun 12, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 507 |
| CEO | Grant E. Pickering |
Contact Details
825 Industrial Road San Carlos,
California 94070 United States
Stock Details
| Ticker Symbol | PCVX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001649094 |
| CUSIP Number | 92243G108 |
| ISIN Number | US92243G1085 |
| SIC Code | 2836 |
Recent News
- 18 days ago / zacks.comWall Street Analysts See an 87.35% Upside in Vaxcyte (PCVX): Can the Stock Really Move This High?
- 1 month ago / zacks.comWall Street Analysts Think Vaxcyte (PCVX) Could Surge 75.6%: Read This Before Placing a Bet
- 1 month ago / globenewswire.comVaxcyte Announces Pricing of Concurrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes
- 1 month ago / seekingalpha.comVaxcyte: 'Strong Buy' On VAX-31 Trial Win IPD VAX-31 And Additional Readouts 1st Half 2027
- 1 month ago / marketbeat.comVaxcyte's VAX-31 Meets All Primary Endpoints in Pivotal Phase III OPUS-1 Trial
- 1 month ago / globenewswire.comVaxcyte Announces Commencement of Proposed Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes
- 1 month ago / seekingalpha.comVaxcyte, Inc. (PCVX) Discusses Top Line Results From OPUS-1 Phase 3 Trial of VAX-31 Pneumococcal Vaccine Candidate Transcript
- 1 month ago / proactiveinvestors.comVaxcyte shares surge on late-stage vaccine trial success
- 1 month ago / barrons.comVaxcyte Stock Spikes 57% as Lead Vaccine Candidate Takes Aim at Pfizer and Merck
- 1 month ago / benzinga.comVaxcyte Stock Hits New 52-Week High - Here's Why
Add to Watchlist
Select watchlists to add or remove PCVX